Ebola viral disease: What should be done to combat the epidemic in 2014?

Ebola virus disease (EVD) was defined first in 1976. Since then, more than 24 epidemics have been reported from Africa, predominantly with the Zaire species. On 21 March 2014, the current West Africa outbreak was reported by the World Health Organization, the largest one ever recorded. The Congo epidemic was reported in July 2014. It was considered that the two epidemics had unrelated origins with 96.8% identical genomic sequence of the virus. EVD outbreaks occurred in areas with limited resources but it has a potentially global effect due to the possibility of imported infection and the potential misuse of the virus as a bioweapon agent. Although EVD is a zoonotic disease with the reservoir of fruit bats, human-to-human transmission is essential in the spread of the infection. The case-fatality rate of EVD was reported as 70.8%. There is no approved prophylaxis, effective treatment, or licensed vaccine. Early diagnosis and isolation of the patients, contact tracing, appropriate use of personal protective equipment , and adherence to the guidance for safe funeral practices constitute the essential requirements to control the epidemics. This article provides a review of the literature regarding the characteristics and management of EVD outbreak.

Ebola viral disease: What should be done to combat the epidemic in 2014?

Ebola virus disease (EVD) was defined first in 1976. Since then, more than 24 epidemics have been reported from Africa, predominantly with the Zaire species. On 21 March 2014, the current West Africa outbreak was reported by the World Health Organization, the largest one ever recorded. The Congo epidemic was reported in July 2014. It was considered that the two epidemics had unrelated origins with 96.8% identical genomic sequence of the virus. EVD outbreaks occurred in areas with limited resources but it has a potentially global effect due to the possibility of imported infection and the potential misuse of the virus as a bioweapon agent. Although EVD is a zoonotic disease with the reservoir of fruit bats, human-to-human transmission is essential in the spread of the infection. The case-fatality rate of EVD was reported as 70.8%. There is no approved prophylaxis, effective treatment, or licensed vaccine. Early diagnosis and isolation of the patients, contact tracing, appropriate use of personal protective equipment , and adherence to the guidance for safe funeral practices constitute the essential requirements to control the epidemics. This article provides a review of the literature regarding the characteristics and management of EVD outbreak.

Kaynakça

Polonsky JA, Wamala JF, de Clerck H, Van Herp M, Sprecher A, Porten K, Shoemaker T. Emerging filoviral disease in Uganda: proposed explanations and research directions. Am J Trop Med Hyg 2014; 90: 790–793.

World Health Organization. Ebola Hemorrhagic Fever. Geneva, Switzerland: WHO; 2010. Available at http://www. who.int/mediacentre/factsheets/fs103/en/. 3. MacNeil A, Rollin PE. Ebola and Marburg hemorrhagic fevers: neglected tropical diseases? PLoS Negl Trop Dis 2012; 6: e1546.

Bray M, Chertow DS. Epidemiology, pathogenesis, and clinical manifestations of Ebola and Marburg virus disease. UpToDate; 2014. Available at http://www.uptodate.com/contents/ epidemiology-and-pathogenesis-of-ebola-virus-disease. 5. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377: 849–862.

Bagcchi S. Ebola haemorrhagic fever in west Africa. Lancet Infect Dis 2014; 14: 375.

World Health Organization  Ebola  Response Team. Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med 2014; 371: 1481–1495.

Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011; 204: 810–816.

Piot P, Bureau P, Breman G, Heymann D, Kintoki V, Masamba M, Mbuyi M, Miatudila M, Ruppol F, Nieuwenhove SV et al. Clinical aspects of Ebola virus infection in Yambuku area, Zaire, 1976. In: Pattyn S, editor. Ebola Virus Haemorrhagic Fever. Amsterdam, the Netherlands: Elsevier; 1978. pp. 17–21.

Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 2007; 196: 364–371.

Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, Nichol ST, Ksiazek TG, Rollin PE. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007; 196: 142–147.

Kucharski AJ, Piot P. Containing Ebola virus infection in West Africa. Euro Surveill 2014; 19: 20899.

Gilsdorf A, Morgan D, Leitmeyer K. Guidance  for  contact tracing of cases of Lassa fever, Ebola or Marburg haemorrhagic fever on an airplane: results of a European expert consultation. BMC Public Health 2012; 12: 1014.

Fischer WA 2nd, Hynes NA, Perl TM. Protecting  health care  workers  from  Ebola: personal protective equipment is critical but is not enough. Ann Intern Med 2014; 161: 753–754.

World Health Organization. Interim Infection Prevention and Control Guidance for Care of Patients with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health- Care Settings, with Focus on Ebola. Geneva, Switzerland: WHO; 2014. Available at http://apps.who.int/iris/ bitstream/10665/130596/1/WHO_HIS_SDS_2014.4_eng. pdf?ua=1&ua=1&ua=1.

Raabe VN, Borchert M. Infection control during  filoviral hemorrhagic fever outbreaks. J Glob Infect Dis 2012; 4: 69–74.

World Health Organization. Case Definition Recommendations for Ebola or Marburg Virus Diseases. Geneva, Switzerland: WHO; 2014. Available at http://www.who.int/csr/resources/ publications/ebola/ebola-case-definition-contact-en. pdf?ua=1.

Centers for Disease Control and Prevention. Case Definition for Ebola Virus Disease (EVD). Atlanta, GA, USA: CDC; 2014. Available at http://www.cdc.gov/vhf/ebola/hcp/case- definition.html.

Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields Virology. 6th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2006. pp. 1409–1448.

Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, Bressler D, Williams AJ, Peters CJ, Rodriguez L, Feldmann H et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola haemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. J Infect Dis 1999; 179: 28–35.

Elliott LH, McCormick JB, Johnson KM. Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol 1982; 16: 704–708.

Towner JS, Sealy TK, Ksiazek TG, Nichol ST. High-throughput molecular detection of haemorrhagic fever virus threats with applications for outbreak settings. J Infect Dis 2007; 196: 205– 212.

World Health Organization. Consultation on Potential Ebola Therapies and Vaccines - Background Document for Participants. Geneva, Switzerland: WHO; 2014. Available at http://www.who.int/csr/disease/ebola/ebola-new- interventions-02-sep-2014.pdf?ua=1.

Kaynak Göster

Bibtex @ { tbtkmedical148778, journal = {Turkish Journal of Medical Sciences}, issn = {1300-0144}, eissn = {1303-6165}, address = {}, publisher = {TÜBİTAK}, year = {2015}, volume = {45}, pages = {1 - 5}, doi = {10.3906/sag-1411-37}, title = {Ebola viral disease: What should be done to combat the epidemic in 2014?}, key = {cite}, author = {Baştuğ, Aliye and Bodur, Hürrem} }
APA Baştuğ, A , Bodur, H . (2015). Ebola viral disease: What should be done to combat the epidemic in 2014? . Turkish Journal of Medical Sciences , 45 (1) , 1-5 . DOI: 10.3906/sag-1411-37
MLA Baştuğ, A , Bodur, H . "Ebola viral disease: What should be done to combat the epidemic in 2014?" . Turkish Journal of Medical Sciences 45 (2015 ): 1-5 <https://dergipark.org.tr/tr/pub/tbtkmedical/issue/12385/148778>
Chicago Baştuğ, A , Bodur, H . "Ebola viral disease: What should be done to combat the epidemic in 2014?". Turkish Journal of Medical Sciences 45 (2015 ): 1-5
RIS TY - JOUR T1 - Ebola viral disease: What should be done to combat the epidemic in 2014? AU - Aliye Baştuğ , Hürrem Bodur Y1 - 2015 PY - 2015 N1 - doi: 10.3906/sag-1411-37 DO - 10.3906/sag-1411-37 T2 - Turkish Journal of Medical Sciences JF - Journal JO - JOR SP - 1 EP - 5 VL - 45 IS - 1 SN - 1300-0144-1303-6165 M3 - doi: 10.3906/sag-1411-37 UR - https://doi.org/10.3906/sag-1411-37 Y2 - 2021 ER -
EndNote %0 Turkish Journal of Medical Sciences Ebola viral disease: What should be done to combat the epidemic in 2014? %A Aliye Baştuğ , Hürrem Bodur %T Ebola viral disease: What should be done to combat the epidemic in 2014? %D 2015 %J Turkish Journal of Medical Sciences %P 1300-0144-1303-6165 %V 45 %N 1 %R doi: 10.3906/sag-1411-37 %U 10.3906/sag-1411-37
ISNAD Baştuğ, Aliye , Bodur, Hürrem . "Ebola viral disease: What should be done to combat the epidemic in 2014?". Turkish Journal of Medical Sciences 45 / 1 (Mart 2015): 1-5 . https://doi.org/10.3906/sag-1411-37
AMA Baştuğ A , Bodur H . Ebola viral disease: What should be done to combat the epidemic in 2014?. Turkish Journal of Medical Sciences. 2015; 45(1): 1-5.
Vancouver Baştuğ A , Bodur H . Ebola viral disease: What should be done to combat the epidemic in 2014?. Turkish Journal of Medical Sciences. 2015; 45(1): 1-5.
IEEE A. Baştuğ ve H. Bodur , "Ebola viral disease: What should be done to combat the epidemic in 2014?", Turkish Journal of Medical Sciences, c. 45, sayı. 1, ss. 1-5, Mar. 2015, doi:10.3906/sag-1411-37

18422 16491

Arşiv
Sayıdaki Diğer Makaleler

Protective effects of royal jelly against testicular damage in streptozotocin-induced diabetic rats

Turan KARACA, Selim DEMİRTAŞ, İhsan KARABOĞA, Süleyman AYVAZ

Protective effects of erdosteine, vitamin E, and vitamin C on renal injury induced by the ischemia-reperfusion of the hind limbs in rats

Rana SIRMALI, Abdullah ARMAĞAN, Faruk ÖKTEM, Efkan UZ, Aynur KIRBAŞ, Soner DÖNMEZ, Hacı Ramazan YILMAZ, Mesrur Selçuk SILAY, Mehmet SIRMALI

Serum VEGF levels in gastric cancer patients: correlation with clinicopathological parameters

Celal İsmail BİLGİÇ, Mesut TEZ

A new utilization area for hyperbaric oxygen? Improving quality of stored blood

Hakan AY, Ramazan YÜKSEL, Kemal ŞİMŞEK, Turgut TOPAL, Özgur YEŞİLYURT, Şükrü ÖTER, Ahmet KORKMAZ, Mehmet ÖZLER, Bülent UYSAL, Halil YAMAN, Orhan BEDİR, Hayati BİLGİÇ

Utility of M30, an apoptotic serum marker, in liver diseases

Akif ALTINBAŞ, Şahin ÇOBAN, Ömer BAŞAR, Osman YÜKSEL

Prognostic value of hemostasis-related parameters for prediction of organ dysfunction and mortality in sepsis

Dunja MIHAJLOVIC, Dajana LENDAK, Gorana MITIC, Tatjana CEBOVIC, Biljana DRASKOVIC, Aleksandra NOVAKOV, Snezana BRKIC

A molecular epidemiological investigation of multistate outbreaks of Salmonella Enteritidis from clinical and environmental samples in Turkey, 2000-2010

Sümeyra ACAR, Belkıs LEVENT, Ekrem ATALAN

Comparative study of virulence factors among ESβL-producing and nonproducing Pseudomonas aeruginosa clinical isolates

Maha Abd El Fattah KHALIL, Fatma IBRAHIM SONBOL, Abdel Fattah Badr MOHAMED, Sameh Samir ALI

An in vitro and in vivo investigation of the cytotoxic effects of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester and bortezomib in multiple myeloma cells

Ertan ALTAYLI, Özgür KORU, Önder ÖNGÖRÜ, Tayfun İDE, Cengizhan AÇIKEL, Meral SARPER, Mualla Pınar ELÇİ, Rahşan ILIKÇI SAĞKAN, Erhan ASTARCI, Duran TOK, Salim ÖZENÇ, Ali Uğur URAL, Ferit AVCU

Effects on quinolone resistance due to the biofilm formation activity in Ureaplasma urealyticum

Chunyan FENG, Ya HUANG, Yunsong YU, Guorong DUAN, Yuying DAI, Ke DONG, Qingtian LI